These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21680782)

  • 1. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
    Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
    J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1a.
    Hu X; Olivier K; Polack E; Crossman M; Zokowski K; Gronke RS; Parker S; Li Z; Nestorov I; Baker DP; Clarke J; Subramanyam M
    J Pharmacol Exp Ther; 2011 Sep; 338(3):984-96. PubMed ID: 21690216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
    Hu X; Cui Y; White J; Zhu Y; Deykin A; Nestorov I; Hung S
    Br J Clin Pharmacol; 2015 Mar; 79(3):514-22. PubMed ID: 25265472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
    Kieseier BC; Arnold DL; Balcer LJ; Boyko AA; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A; Sheikh SI; Calabresi PA
    Mult Scler; 2015 Jul; 21(8):1025-35. PubMed ID: 25432952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
    Mager DE; Neuteboom B; Jusko WJ
    Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.
    Seddighzadeh A; Hung S; Selmaj K; Cui Y; Liu S; Sperling B; Calabresi PA
    Expert Opin Drug Deliv; 2014 Nov; 11(11):1713-20. PubMed ID: 25073663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients: A phase 3, randomized, non-inferiority clinical trial (PEGINTEGRITY).
    Shaygannejad V; Ashtari F; Saeidi M; Beladi Moghadam N; Ghalyanchi Langroodi H; Baghbanian SM; Abolfazli R; Ghiasian M; Ayromlou H; Asadollahzadeh E; Sabzvari A; Kafi H; Azimi Saeen A
    Mult Scler Relat Disord; 2024 Oct; 90():105839. PubMed ID: 39217809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Ginsberg M; Rittweger K; Vuky J; Yu R; Fettner S; Hooftman L
    J Clin Oncol; 2001 Mar; 19(5):1312-9. PubMed ID: 11230473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study.
    Gold R; Rieckmann P; Chang P; Abdalla J;
    Eur J Neurol; 2005 Aug; 12(8):649-56. PubMed ID: 16053475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].
    Boyko AN; Boyko OV; Bakhtiyarova KZ; Gusev EI; Dudin VA; Zaslavsky LG; Malkova NA; Parshina YV; Poverennova IY; Siverceva SA; Totolyan NA; Shchur SG; Fedulov AS; Khabirov FA; Bolsun DD; Zinkina-Orikhan AV; Linkova YN; Chernovskaya TV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(1):62-71. PubMed ID: 35175704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
    Hoy SM
    CNS Drugs; 2015 Feb; 29(2):171-9. PubMed ID: 25666445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
    Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
    J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia.
    Talpaz M; Rakhit A; Rittweger K; O'Brien S; Cortes J; Fettner S; Hooftman L; Kantarjian H
    Clin Cancer Res; 2005 Sep; 11(17):6247-55. PubMed ID: 16144928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
    Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
    Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.